

10-03-00

A

Box seq

**Patent Application Transmittal**  
(only for new nonprovisional applications under 37 C.F.R. 1.53(b))

Correspondence Address:  
**FROMMER LAWRENCE & HAUG LLP**  
745 Fifth Avenue  
New York, New York 10151  
Tel. (212) 588-0800 Fax: (212) 588-0500

Date: September 29, 2000  
Re: 454313-3160

JC836 U.S. PTO  
09/677672  
10/02/00

TO: HONORABLE ASSISTANT COMMISSIONER FOR PATENTS  
Box: NEW PATENT APPLICATION, Washington, D.C. 20231

Sir:

With reference to the filing in the United States Patent and Trademark Office of an application for patent in the name of:

**AUDONNET Jean-Christophe Francis and MINKE Jules Maarten**

entitled: **ADJUVANT-CONTAINING DNA VACCINES**

☐ This is an application of a small entity under 37 CFR 1.9(f).

☐ Small Entity Verified Statement is enclosed (unsigned)

The following are enclosed:

- ☒ Specification ( 28 pages, plus 1 page of abstract on page 32.)
- ☒ Sheet(s) of Drawings (6 PAGES) (FIGS. 1 to 6)
- ☒ 14 Claims (pp. 29-31)
- ☒ Oath or Declaration and Power of Attorney (1 page)
- ☒ Information Disclosure Statement and FORM PTO-1449 (in duplicate).
- ☒ Paper form and computer readable form of Sequence Listings.
- ☒ Statement to support filing and submission of sequence listing in accordance with 37 C.F.R. §§ 1.821-1.825
- ☒ Filing fee in the amount of **\$690.00**.

Kindly accord the application an October 2, 2000 filing date.

Respectfully submitted,  
FROMMER LAWRENCE & HAUG LLP  
Attorneys for Applicants

By:

*Thomas J. Kowalewski*  
Thomas J. Kowalewski  
Reg. No. 32,147  
Phone (212) 588-0800

**EXPRESS MAIL**

Mailing Label Number: EL 375 195 811 US

Date of Deposit: October 2, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

*Kenneth Patterson*  
(Typed or printed name of person mailing paper or fee)

*[Signature]*  
(Signature of person mailing paper or fee)

YL0286

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : AUDONNET Jean-Christophe Francis and MINKE Jules Maarten  
Serial No. : Not Yet Known  
Filing Date : Herewith  
For : ADJUVANT-CONTAINING DNA VACCINES  
Examiner : Not Yet Known  
Art Unit : Not Yet Known

745 Fifth Avenue  
New York, New York 10151


**EXPRESS MAIL**

Mailing Label Number: EL 375 195 811 US

Date of Deposit: October 2, 2000

I hereby certify that this paper or fee is being deposited with the  
United States Postal Service "Express Mail Post Office to  
Addressee" Service under 37 CFR 1.10 on the date indicated  
above and is addressed to: Assistant Commissioner for Patents,  
Washington, D.C. 20231.

Kenneth Patterson  
(Typed or printed name of person mailing paper or fee)

  
(Signature of person mailing paper or fee)

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Kindly amend the application, without any prejudice, without any admission, without any  
surrender of subject matter, and without any intention of creating any estoppel as to equivalents  
as follows:

**IN THE SPECIFICATION**

On page 1, before line 1, please insert

-- **TITLE OF THE INVENTION**

ADJUVANT-CONTAINING VACCINES

**CROSS-REFERENCE TO RELATED APPLICATIONS/INCORPORATION BY  
REFERENCE**

This application is a continuation-in-part of PCT/FR99/00666, filed on March 22, 1999 which claims the priority benefits of French Patent Application No. 98/04409, filed on April 3, 1998. Each of these applications, as well as each document or reference cited in each of these applications (including during the prosecution; "application cited documents"), and each foreign application or patent corresponding to and/or claiming priority from any of these applications, and each of the documents cited or referenced in each of the application cited documents, are hereby expressly incorporated herein by reference in their entirety. More generally, documents or references are cited in this text; and, each of these documents or references ("herein-cited documents or references"), as well as each document or reference cited in each of the herein-cited documents or references (including any manufacturer's specifications, instructions, etc.), is hereby expressly incorporated herein by reference.

**FIELD OF THE INVENTION** --.

Page 1, line 9, please insert

-- **BACKGROUND** --

Page 1, line 31, please insert

-- **SUMMARY OF THE INVENTION** --

Page 2, line 8, please insert

-- **DETAILED DESCRIPTION** --

Page 12, line 1, please replace "list of figures," with -- **BRIEF DESCRIPTION OF  
THE DRAWINGS** --

**REMARKS**


This Preliminary Amendment merely adds a lineage, and headings, to place the application in better condition for examination.

No fee is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any fee is required for the consideration of this Preliminary Amendment, the Assistant Commissioner is authorized to charge such fee or credit any overpayment to Deposit Account 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

By:



Thomas J. Kowalski

Reg. No. 32,147

Phone (212) 588-0800

Fax (212) 588-0500

The present invention relates to an improvement to DNA vaccines, also called plasmid or polynucleotide vaccines, comprising and expressing in vivo one or more heterologous genes. It relates in particular to such improved vaccines, to the use of particular adjuvant compounds for using such vaccines as well as to the vaccination methods relating thereto. Its subject is also a method of preparing these vaccines.

Patent applications WO-A-90 11092, WO-A-93 19183, WO-A-94 21797, WO-A-95 11307 and WO-A-95 20660 have made use of the recently developed technique of polynucleotide vaccines. It is known that these vaccines use a plasmid capable of expressing, in the cells of the host, a gene inserted into the plasmid and encoding an immunogen. All routes of administration have been proposed (intraperitoneal, intravenous, intramuscular, transcutaneous, intradermal, mucosal, and the like). Various means of vaccination may also be used, such as DNA deposited at the surface of gold particles and discharged so as to penetrate into the cells of the skin of the animal (Tang et al., Nature 356, 152-154, 1992) and liquid jet injectors make it possible to transfect into the skin, muscle, fatty tissues and mammary tissues (Furth et al., Analytical Biochemistry, 205, 365-368, 1992).

These polynucleotide vaccines may be used in the form of naked DNA or in the form of a complex with liposomes or cationic lipids.

The objective of the invention is to enhance the efficacy of DNA vaccines by providing new vaccine formulations which are simple and easy to prepare.

Its objective is also to provide such a solution which does not cause strong interactions between the DNA and the other ingredient, which are capable of leading to the formation of a complex.

Its objective is also to provide such a solution which makes it possible, either by simple mixing, to prepare stable vaccines, formulated in a

liquid form, or to easily prepare a liquid vaccine by mixing immediately before use.

5 The applicant has found, surprisingly, that the carbomer class of compounds meet these various objectives and in particular are capable of acting as adjuvants for naked DNA vaccines in a simple manner but in very advantageous proportions.

10 The subject of the present invention is therefore a DNA vaccine comprising a naked DNA, in particular circular vaccinal plasmid, supercoiled or otherwise, or a linear DNA molecule, incorporating and expressing in vivo a nucleotide sequence encoding an antigenic polypeptide, preferably a gene of a pathogenic agent, and at least one adjuvant compound  
15 chosen from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl derivative.


20 Naked DNA is understood to mean, as is nowadays commonly accepted, a DNA transcription unit in the form of a polynucleotide sequence comprising at least one nucleotide sequence encoding an antigenic polypeptide or an antigen of one valency and the elements necessary for its expression in vivo. The circular plasmid form, supercoiled or otherwise, is preferred. Valency in the  
25 present invention is understood to mean at least one antigen providing protection against a pathogen, it being possible for the valency to contain, as sub-valency, one or more natural or modified genes, of one or more strains of the pathogen considered.

30 The preferred adjuvant compounds are the polymers of acrylic or methacrylic acid which are cross-linked, especially with polyalkenyl ethers of sugars or polyalcohols. These compounds are known by the term carbomer (Pharmeuropa Vol. 8, No. 2, June  
35 1996). Persons skilled in the art can also refer to US-A-2 909 462 (incorporated herein by reference) which describes such acrylic polymers cross-linked with a polyhydroxylated compound having at least 3 hydroxyl groups, preferably not more than 8, the hydrogen atoms

of at least three hydroxyls being replaced by unsaturated aliphatic radicals having at least 2 carbon atoms. The preferred radicals are those containing from 2 to 4 carbon atoms, e.g. vinyls, allyls and other ethylenically unsaturated groups. The unsaturated radicals may themselves contain other substituents, such as methyl. The products sold under the name Carbopol® (BF Goodrich, Ohio, USA) are particularly appropriate. They are cross-linked with an allyl sucrose or with allyl pentaerythritol. Among them, there may be mentioned Carbopol® 974P, 934P and 971P.

Among the copolymers of maleic anhydride and alkenyl derivative, the copolymers EMA® (Monsanto) which are copolymers of maleic anhydride and ethylene, linear or cross-linked, for example cross-linked with divinyl ether, are preferred. Reference may be made to J. Fields et al., Nature, 186: 778-780, 4 June 1960, incorporated herein by reference.

From the point of view of their structure, the polymers of acrylic or methacrylic acid and the copolymers EMA® are preferably formed of basic units of the following formula:



in which:

- R<sub>1</sub> and R<sub>2</sub>, which are identical or different, represent H or CH<sub>3</sub>
- x = 0 or 1, preferably x = 1
- y = 1 or 2, with x + y = 2

For the copolymers EMA®, x = 0 and y = 2. For the carbomers, x = y = 1.

The dissolution of these polymers in water leads to an acid solution which will be neutralized, preferably to physiological pH, in order to give the adjuvant solution into which the vaccine itself will be

incorporated. The carboxyl groups of the polymer are then partly in  $\text{COO}^-$  form.

Preferably, a solution of adjuvant according to the invention, especially of carbomer, is prepared in distilled water, preferably in the presence of sodium chloride, the solution obtained being at acidic pH. This stock solution is diluted by adding it to the desired quantity (for obtaining the desired final concentration), or a substantial part thereof, of water charged with NaCl, preferably physiological saline (NaCl 9 g/l) all at once or in several portions with concomitant or subsequent neutralization (pH 7.3 to 7.4), preferably with NaOH. This solution at physiological pH will be used as it is for mixing with the vaccine, which may be especially stored in freeze-dried, liquid or frozen form.

The polymer concentration in the final vaccine composition will be 0.01% to 2% w/v, more particularly 0.06 to 1% w/v, preferably 0.1 to 0.6% w/v.

For the vaccination of pigs, the invention may apply in particular to vaccination against Aujeszky's disease virus (PRV or pseudorabies virus), porcine influenza virus (SIV), porcine reproductive and respiratory syndrome virus (PRRS virus), porcine parvovirus (PPV virus), hog cholera virus (HCV virus) and bacterium responsible for actinobacillosis (*A. pleuropneumoniae*). The plasmids which can be used in the invention comprise, for each valency, one or more of the genes encoding major immunogens of the pathogenic agents considered. There may be mentioned in particular the gB and gD genes for the Aujeszky's disease virus, the HA, NP and N genes for the porcine influenza virus, the ORF5 (E), ORF3 and ORF6 (M) genes for the PRRS virus, VP2 for the parvovirus, E2, E1 + E2, E1 + E2 + C for the hog cholera virus and apxI, apxII and apxIII for *A. pleuropneumoniae*. In a particularly advantageous manner, reference may be made to the polynucleotide vaccine formulas described in patent application WO-A-98 03 658 (FR-A-2,751,224)



which is incorporated herein by reference and relates to vaccines against pig reproductive and respiratory pathologies. This application describes in particular a number of plasmids which may be directly used by way of  
5 examples in the context of the present invention in combination with an adjuvant according to the invention. Persons skilled in the art will thus be able to combine, with the adjuvants in accordance with the invention, the plasmids specifically described in this  
10 previous application, namely pAB090 comprising the gB gene of the PRV virus, pPB098 comprising the gD gene of the PRV virus, pPB143 comprising the HA gene of porcine influenza, strain H1N1, pPB142 comprising the NP gene of porcine influenza, strain H1N1, pPB144 comprising  
15 the HA gene of porcine influenza, strain H3N2, pPB132 comprising the NP gene of porcine influenza, strain H3N2, pAB025 comprising ORF5 of the PRRS virus, strain Lelystad, pAB001 comprising ORF5 of the PRRS virus, strain USA, pAB091 comprising ORF3 of the PRRS virus,  
20 strain Lelystad, pAB092 comprising ORF3 of the PRRS virus, strain USA, pAB004 comprising the VP2 gene of the porcine parvovirus, pAB069 comprising the E1 gene of the hog cholera virus (HCV), pAB061 comprising the E2 gene of the hog cholera virus (HCV), pAB162  
25 comprising the deleted apxI gene of A. pleuropneumoniae, pPB163 comprising the deleted apxII gene of A. pleuropneumoniae, pPB174', pPB189 and pPB190 comprising the deleted apxIII gene of A. pleuropneumoniae.

30 For the vaccination of horses, there may be mentioned in particular vaccination against equine rhinopneumonia virus (EHV), especially type 1 (EHV-1) and type 4 (EHV-4), against the equine influenza virus EIV, against tetanus (Cl.tetani), against the Eastern  
35 encephalitis virus (EEV), Western encephalitis virus (WEV) and Venezuelan encephalitis virus (VEV), as well as against Lyme disease (B. burgdorferi), against equine arthritis (EAV) and against rabies. Among the genes encoding major immunogens which can be used

according to the invention, there may be mentioned gB and gD genes for the equine rhinopneumonia valency, especially types 1 and 4, the HA, NA and NP genes for equine influenza, the C subunit, optionally modified by mutation or deletion, for the tetanus valency, the C and E2 genes for encephalites, the OspA, OspB and p100 genes for Lyme disease, the E, M and N genes for equine arthritis and the G gene for rabies. Such polynucleotide vaccine formulas against horse pathologies are described in particular in patent application WO-A-98 03 198 (FR-A-2,751,226) which is incorporated herein by reference. This application describes a number of plasmids which can be directly used in the present invention in combination with an adjuvant in accordance with the invention. Persons skilled in the art will therefore be able to combine, with the adjuvant in accordance with the invention, a plasmid as precisely described in this application, namely pAB042 comprising the gB gene of the EHV-1 virus, pAB031 comprising the gB gene of the EHV-4 virus, pAB013 comprising the gD gene of the EHV-1 virus, pAB032 comprising the gD gene of the EHV-4 virus, pAB043 comprising the HA gene of equine influenza, Prague strain, pAB033 comprising the HA gene of equine influenza, Suffolk strain, pAB099 comprising the HA gene of equine influenza, Fontainebleau strain, pAB085 comprising the NP gene of equine influenza, Prague strain, pAB084 comprising the NP gene of equine influenza, Jillin strain, pAB070 comprising the gene for the C subunit of the tetanus toxin, pAB017 comprising the OspA gene of *Borrelia burgdorferi*, pAB094 comprising the E2 gene of the Eastern encephalitis virus, pAB093 comprising the C gene of the Eastern encephalitis virus, pAB096 comprising the E2 gene of the Western encephalitis virus, pAB095 comprising the C gene of the Western encephalitis virus, pAB098 comprising the E2 gene of the Venezuelan encephalitis virus, pAB097 comprising the C gene of the

Venezuelan encephalitis virus and pAB041 comprising the G gene of the rabies virus.

For vaccination of dogs, the invention may apply in particular to vaccination against Canine Distemper (Carré's disease) virus (CDV), canine parvovirus (CPV), canine coronavirus (CCV), canine herpesvirus (CHV), Lyme disease and rabies. Among the genes encoding major immunogens which can be used in the context of the present invention, there may be mentioned most particularly the HA, F, M and N genes for the Canine Distemper virus, the VP2 gene for the canine parvovirus, the S and M genes for the canine coronavirus (CCV), the gB and gD genes for the CHV virus, the OspA and OspB and p100 genes for B. burgdorferi (Lyme disease) and the G gene for rabies. Such polynucleotide vaccine formulas are described in particular in patent application WO-A-98 03 199 (FR-A-2,751,227) which is incorporated herein by reference. Persons skilled in the art will therefore be able to refer to the plasmids described in this application, in combination with the adjuvants in accordance with the invention. Most particularly, they will be able to combine, with the adjuvants in accordance with the invention, the specific plasmids described in this application, namely pAB044 comprising the HA gene of CDV, pAB036 comprising the F gene of CDV, pAB024 comprising the VP2 gene of the canine parvovirus, pAB021 comprising the S gene of CCV, pAB022 comprising the M gene of CCV, pAB037 comprising the gB gene of CHV, pAB038 comprising the gD gene of CHV, pAB017 comprising the OspA gene of B. burgdorferi and pAB041 comprising the G gene of the rabies virus.

For vaccination of bovines, the invention may apply in particular to vaccination against the bovine herpesvirus type 1 or 5 (BHV-1 and BHV-5, responsible for the nervous form of the disease), the bovine respiratory syncytial virus (BRSV), the mucosal disease virus or bovine pestivirus (BVD), the bovine parainfluenza virus type 3 (BPI-3). Among the genes

encoding the major immunogens allowing vaccination against these viruses, there may be mentioned in particular the gB and gD genes for the bovine herpesvirus, F and G for the bovine respiratory syncytial virus, E2, C + E1 + E2 and E1 + E2 for the mucosal disease virus, HN and F for the bovine parainfluenza virus type 3. Such vaccine formulas are described in particular in patent application WO-A-98 03 200 (FR-A-2,751,229) which is incorporated herein by reference. Persons skilled in the art will therefore be able to use the plasmids described in this application in combination with the adjuvants in accordance with the invention. In particular, they will be able to combine, with the adjuvants in accordance with the invention, the plasmids specifically described in this application, namely pPB156 comprising the gB gene of BHV-1, pAB087 comprising the gD gene of BHV-1, pAB011 comprising the F gene of BRSV, pAB012 comprising the G gene of BRSV, pAB058 comprising the C gene of BVD, pAB059 comprising the E1 gene of BVD, pAB060 comprising the E2 gene of BVD, pAB071 comprising the HN gene of BPI-3, pAB072 comprising the F gene of BPI-3.

For the vaccination of cats, the invention may apply in particular to vaccination against the feline leukemia virus FeLV, in particular subtypes A and B, the feline panleukopenia virus (FPV), the feline infectious peritonitis virus (FIPV), the coryza virus or feline herpesvirus (FHV), the feline caliciviro-sis virus (FCV), the feline immunodeficiency virus (FIV) and the rabies virus (rhabdovirus). Among the genes encoding major immunogens allowing vaccination against these pathogens, there may be mentioned in particular the env and gag/pol genes for feline leukemia, VP2 for panleukopaenia, M and modified S (FR-A-2,724,385 incorporated herein by reference) for infectious peritonitis, gB and gD for coryza, capsid for caliciviro-sis, env and gag/pro for feline immuno-deficiency and G for rabies. Polynucleotide vaccine formulas are thus described in patent application

WO-A-98- 03 660 (FR-A-2,751,223) which is incorporated herein by reference. Persons skilled in the art will be able to combine plasmids as described in this application with the adjuvants in accordance with the invention. In particular, they will be able to combine, with the adjuvants in accordance with the invention, the plasmids specifically described in this application, namely pPB179 comprising the env gene of the FeLV-A virus, pPB180 comprising the env gene of the FeLV-B virus, pPB181 comprising the gag/pol gene of FeLV-A, pAB009 comprising the VP2 gene of FPV, pAB053 comprising the modified S gene (FR-A-2 724 385) of the FIPV virus, pAB052 comprising the M gene of FIPV, pAB056 comprising the N gene of FIPV, pAB028 comprising the gB gene of FHV, pAB029 comprising the gD gene of FHV, pAB010 comprising the C gene of FCV, pAB030 comprising the env gene of FIV, pAB083 comprising the gag/pro gene of FIV and pAB041 comprising the G gene of the rabies virus.

For vaccination of avian species, the invention may apply in particular to vaccination against the Marek's disease virus (MDV), the Newcastle disease virus (NDV), the Gumboro disease virus (IBDV or Infectious Bursal Disease Virus), the infectious bronchitis virus (IBV), the infectious anemia virus (CAV), the infectious laryngotracheitis virus (ILTV), the encephalomyelitis virus (AEV or avian leukosis virus ALV), the pneumovirosis virus or pneumovirus, and the avian influenza virus. Among the genes encoding the major immunogens which can be used in the present invention, there may be mentioned most particularly the gB and gD genes for the Marek's disease virus, HN and F for the Newcastle disease virus, VP2 for the Gumboro disease virus, S, M and N for the infectious bronchitis virus, C + NS1 for the infectious anemia virus, gB and gD for the infectious laryngotracheitis virus, env and gag/pro for the encephalomyelitis virus, F and G for the pneumovirosis virus and HA, N and NP for avian influenza. Such polynucleotide vaccine formulas are

described in patent application WO-A-98 03 659 (FR-A-2,751,225) which is incorporated herein by reference. Persons skilled in the art will therefore be able to refer to the plasmids described in this application in order to combine them with the adjuvants in accordance with the invention. Most particularly, persons skilled in the art will be able to combine, with the adjuvants in accordance with the invention, the plasmids described specifically in this application, namely pAB045 comprising the gB gene of MDV, pAB080 comprising the gD gene of MDV, pAB046 comprising the HN gene of NDV, pAB047 comprising the F gene of NDV, pAB048 comprising the VP2 gene of IBDV, pAB049 comprising the S1 gene of IBV, pAB050 comprising the M gene of IBV, pAB051 comprising the N gene of IBV, pAB054 comprising the VP1 gene of CAV, pAB055 comprising the VP2 gene of CAV, pAB076 comprising the gB gene of ILTV, pAB089 comprising the gD gene of ILTV, pAB086 comprising the env gene of AEV, pAB081 comprising the gag/pro gene of AEV, pAB082 comprising the G gene of the pneumovirus, pAB077 comprising the HA gene of avian influenza, strain H2N2, pAB078 comprising the HA gene of avian influenza, strain H7N7, pAB088 comprising the NP gene of avian influenza, strain H1N1, pAB079 comprising the N gene of avian influenza, strain H7N1.

Each naked, in particular plasmid, DNA comprises a promoter capable of bringing about, in the host cells, the expression of the gene inserted under its control. It will be in general a strong eukaryotic promoter and in particular a cytomegalovirus early promoter CMV-IE, of human or murine origin, or alternatively possibly of another origin such as rat, pig or guinea pig. In a more general manner, the promoter may either be of viral origin, or of cellular origin. As viral promoter other than CMV-IE, there may be mentioned the SV40 virus early or late promoter or the Rous sarcoma virus LTR promoter. It may also be a promoter coming from the virus from which the gene is derived, for example the actual promoter of the gene.

As cellular promoter, there may be mentioned the promoter of a cytoskeleton gene, such as for example the desmin promoter (Bolmont et al., Journal of Submicroscopic Cytology and Pathology, 1990, 22, 117-122; and Zhenlin et al., Gene, 1989, 78, 243-254), or alternatively the actin promoter. When several genes are present in the same naked, in particular plasmid, DNA they may be present in the same transcription unit or in two different units.

Of course, a vaccine may combine, for each of the valencies described above, several genes within the same naked, in particular plasmid, DNA and/or several naked, in particular plasmid, DNAs each comprising one or more genes of the same virus.

The subject of the invention is also multivalent recombinant vaccines, that is to say containing one or preferably two or more naked, in particular plasmid, DNAs expressing antigens for two or more diseases, in the form of a mixture in an adjuvant solution in accordance with the invention.

In the ready-for-use vaccine, the naked DNA, in particular the vaccinal plasmid, is present in the quantities normally used and described in the literature.

The subject of the invention is also a method of vaccination consisting of administering by the parenteral, preferably intramuscular, intradermal, route or by the mucosal route a DNA vaccine in accordance with the invention at the rate of one or more administrations.

The subject of the invention is also the use of the adjuvant compounds in accordance with the invention for the production of adjuvant-containing DNA vaccines as described here.

The invention will now be described in greater detail with the aid of the embodiments taken by way of nonlimiting examples and referring to the accompanying figures.

**List of figures:**

- Figure No. 1: Sequence of the hemagglutinin (HA) gene of the equine influenza virus strain Newmarket 2/93
- Figure No. 2: Sequence of the hemagglutinin (HA) gene of the equine influenza virus strain Kentucky 1/94
- Figure No. 3: Sequence of the neuraminidase (NA) gene of the equine influenza virus strain Newmarket 2/93
- Figure No. 4: Sequence of the neuraminidase (NA) gene of the equine influenza virus strain Kentucky 1/94
- Figure No. 5: Sequence of the nucleoprotein (NP) gene of the equine influenza virus strain Newmarket 2/93
- Figure No. 6: Sequence of the nucleoprotein (NP) gene of the equine influenza virus strain Kentucky 1/94.

**Sequence listing:**

- SEQ ID No. 1: Oligonucleotide CCL007
- SEQ ID No. 2: Oligonucleotide CCL018
- SEQ ID No. 3: Sequence of the HA gene, EIV  
Newmarket 2/93 strain
- SEQ ID No. 4: Oligonucleotide CCL020
- SEQ ID No. 5: Sequence of the HA gene, EIV Kentucky  
1/94 strain
- SEQ ID No. 6: Oligonucleotide AB260
- SEQ ID No. 7: Oligonucleotide AB262
- SEQ ID No. 8: Sequence of the NA gene, EIV  
Newmarket 2/93 strain
- SEQ ID No. 9: Sequence of the NA gene, EIV Kentucky  
1/94 strain
- SEQ ID No. 10: Oligonucleotide CCL019
- SEQ ID No. 11: Oligonucleotide CCL021
- SEQ ID No. 12: Sequence of the NP gene, EIV  
Newmarket 2/93 strain



SEQ ID No. 13: Sequence of the NP gene, EIV Kentucky  
1/94 strain

#### **Example 1: Adjuvant**

The carbomer used in the vaccines in accordance with the present invention is Carbopol® 974P  
5 manufactured by the company BF Goodrich (MW about 3 million).

A stock solution containing 1.5% w/v of Carbopol® 974P was first prepared in distilled water containing sodium chloride at 1 g/l.

10 This stock solution is then used for the manufacture of a solution of Carbopol® in physiological saline at 4 mg/ml. The stock solution is poured into the entire physiological saline (or optionally into most of it) all at once or optionally in several  
15 portions with, each time, adjustment of the pH with the aid of NaOH (for example 1 N or more concentrated) to a value of about 7.3 to 7.4.

A ready-for-use solution of Carbopol® is thereby obtained.  
20

#### **Example 2: Culture of the viruses**

The viruses are cultured on the appropriate cellular system until a cytopathic effect is obtained. The cellular systems to be used for each virus are well  
25 known to the persons skilled in the art. Briefly, cells sensitive to the virus used, cultured in Eagle's minimum essential medium ("MEM" medium) or another appropriate medium, are inoculated with the viral strain studied using a multiplicity of infection of 1.  
30 The infected cells are then incubated at 37°C for the time necessary for the appearance of a complete cytopathic effect (on average 36 hours).

#### **Example 3: Extraction of the viral genomic DNAs**

35 After culture, the supernatant and the lysed cells are harvested and the entire viral suspension is centrifuged at 1000 g for 10 minutes at +4°C in order

to remove the cellular debris. The viral particles are then harvested by ultracentrifugation at 400,000 g for 1 hour at +4°C. The pellet is taken up in a minimum volume of buffer (10 mM Tris, 1 mM EDTA). This concentrated viral suspension is treated with proteinase K (100 µg/ml final) in the presence of sodium dodecyl sulphate (SDS) (0.5% final) for 2 hours at 37°C. The viral DNA is then extracted with a phenol/chloroform mixture and then precipitated with 2 volumes of absolute ethanol. After one night at -20°C, the DNA is centrifuged at 10,000 g for 15 minutes at +4°C. The DNA pellet is dried and then taken up in a minimum volume of sterile ultrapure water. It can then be digested with restriction enzymes.

#### **Example 4: Isolation of the viral genomic RNAs**

The RNA viruses were purified according to techniques well known to persons skilled in the art. The genomic viral RNA of each virus was then isolated using the "guanidium thiocyanate/phenol-chloroform" extraction technique described by P. Chomczynski and N. Sacchi (Anal. Biochem, 1987. **162**. 156-159).

#### **Example 5: Molecular biology techniques**

All the plasmid constructions were carried out using the standard molecular biology techniques described by J. Sambrook et al. (*Molecular Cloning: A Laboratory Manual*. 2nd Edition. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989). All the restriction fragments used for the present invention were isolated using the "Geneclean" kit (BIO101 Inc. La Jolla, CA).

#### **Example 6: RT-PCR technique**

Specific oligonucleotides (containing at their 5' ends restriction sites to facilitate the cloning of the amplified fragments) were synthesized so that they completely cover the coding regions of the genes which

have to be amplified (see specific examples). The reverse transcription reaction (RT) and polymerase chain reaction (PCR) were carried out according to standard techniques (J. Sambrook et al. *Molecular Cloning: A Laboratory Manual*. 2nd Edition. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989). Each RT-PCR reaction was performed with a pair of specific amplimers and taking as template the extracted viral genomic RNA. The amplified complementary DNA was extracted with phenol/chloroform/isoamyl alcohol (25:24:1) before being digested with restriction enzymes.

**Example 7: Plasmid pVR1012**

The plasmid pVR1012 was obtained from Vical Inc. San Diego, CA, USA. Its construction has been described in J. Hartikka et al. (Human Gene Therapy. 1996. 7. 1205-1217) incorporated herein by reference.

**Example 8: Construction of the plasmid pCCL027 (Newmarket 2/93 EIV HA gene)**

An RT-PCR reaction according to the technique described in Example 6 was carried out with the genomic RNA of the equine influenza virus (EIV) (Newmarket 2/93 strain) (Daly et al. J. Gen. Virol. 1996. 77. 661-671), prepared according to the technique described in Example 4, and with the following oligonucleotides:

CCL007 (40 mer) (SEQ ID No.1)  
5' TTGTCGACTCAATCATGAAGACAACCATTATTTTGATACT 3'  
CCL018 (34 mer) (SEQ ID No. 2)  
5' TTGGATCCTTACTCAAATGCAAATGTTGCACCTG 3'

in order to isolate the gene encoding the HA glycoprotein of the equine influenza virus (Newmarket 2/93 strain) (Figure No. 1, SEQ ID No. 3) in the form of a PCR fragment of about 1750 bp. This fragment was purified and then ligated with the vector pCRII (Cat# K2000-01, Invitrogen Corp. Carlsbad, CA) in order to give the plasmid pCCL026. The plasmid pCCL026 was then digested with the restriction enzymes SalI and NotI in

order to isolate an SalI-NotI fragment of 1751 bp containing the Newmarket 2/93 EIV HA gene. This fragment was then ligated with the plasmid pVR1012 (see Example 7), previously digested with SalI and NotI, in order to give the plasmid pCCL027 (6642 bp).

**Example 9: Construction of the plasmid pPB242 (Kentucky 1/94 EIV HA gene)**

10 An RT-PCR reaction according to the technique described in Example 6 was carried out with the genomic RNA of the equine influenza virus (EIV) (Kentucky 1/94 strain) (Daly et al. J. Gen. Virol. 1996. **77**, 661-671), prepared according to the technique described in  
15 Example 4, and with the following oligonucleotides:  
CCL007 (40 mer) (SEQ ID No. 1)  
5' TTGTCGACTCAATCATGAAGACAACCATTATTTTGATACT 3'  
CCL020 (34 mer) (SEQ ID No. 4)  
5' TTGGATCCTTACTCAAATGCAAATGTTGCATCTG 3'  
20 in order to isolate the gene encoding the HA glycoprotein of the equine influenza virus (Kentucky 1/94 strain) (Figure No. 2, SEQ ID No. 5) in the form of a PCR fragment of about 1750 bp. This fragment was purified and then ligated with the vector pCRII (Cat#  
25 K2000-01, Invitrogen Corp. Carlsbad, CA) in order to give the plasmid pCCL028. The plasmid pCCL028 was digested with the restriction enzymes SacI and BamHI in order to isolate an SacI-BamHI fragment of 1153 bp (fragment A) containing the 3' part of the Kentucky  
30 1/94 EIV HA gene. The plasmid pCCL028 was digested with the restriction enzymes SacI and EcoRV in order to isolate a SacI-EcoRV fragment of 621 bp (fragment B) containing the 5' part of the Kentucky 1/94 EIV HA gene. Fragments A and B were then ligated together with  
35 the plasmid pVR1012 (see Example 7), previously digested with EcoRV and BamHI, in order to give the plasmid pPB242 (6688 bp).

**- Example 10: Construction of the plasmid pAB142  
(Newmarket 2/93 EIV NA gene)**

An RT-PCR reaction according to the technique described in Example 6 was carried out with the genomic RNA of the equine influenza virus (EIV) (Newmarket 2/93 strain) (Daly et al. J. Gen. Virol. 1996, **77**, 661-671), prepared according to the technique described in Example 4, with the following oligonucleotides:

AB260 (35 mer) (SEQ ID No. 6)

5' TTTGTGCGACATGAAYCCAAATCAAAARATAATAAC 3'

AB262 (32 mer) (SEQ ID No. 7)

5' TTTGGATCCYTACATCTTTRTCGATGTCAAAGG 3'

in order to isolate the gene encoding the neuraminidase (NA) glycoprotein of the equine influenza virus (Newmarket 2/93 strain) (Figure No. 3, SEQ ID No. 8) in the form of a PCR fragment of about 1430 bp. This fragment was purified and then digested with the restriction enzymes SalI and BamHI in order to isolate a SalI-BamHI fragment of 1418 bp containing the Newmarket 2/93 EIV NA gene. This fragment was then ligated with the plasmid pVR1012 (see Example 7), previously digested with SalI and BamHI, in order to give the plasmid pAB142 (6287 bp).

**Example 11: Construction of the plasmid pPB246  
(Kentucky 1/94 EIV NA gene)**

An RT-PCR reaction according to the technique described in Example 6 was carried out with the genomic RNA of the equine influenza virus (EIV) (Kentucky 1/94 strain) (Daly et al. J. Gen. Virol. 1996, **77**, 661-671), prepared according to the technique described in Example 4, and with the following oligonucleotides: AB260 and AB262 (Example 10) in order to isolate the gene encoding the neuraminidase (NA) glycoprotein of the equine influenza virus (Kentucky 1/94 strain) (Figure No. 4, SEQ ID No. 9) in the form of a PCR fragment of about 1430 bp. This fragment was purified and then digested with the restriction enzymes SalI and BamHI in order to isolate a SalI-BamHI fragment of

1418 bp. containing the Kentucky 1/94 EIV NA gene. This fragment was then ligated with the plasmid pVR1012 (see Example 7), previously digested with SalI and BamHI, in order to give the plasmid pAB116 (6287 bp).

5

**Example 12: Construction of the plasmid pPB245  
(Newmarket 2/93 EIV NP gene)**

An RT-PCR reaction according to the technique described in Example 6 was carried out with the genomic RNA of the equine influenza virus (EIV) (Newmarket 2/93 strain) (Daly et al. J. Gen. Virol. 1996, **77**, 661-671), prepared according to the technique described in Example 4, and with the following oligonucleotides:

CCL019 (25 mer) (SEQ ID No. 10)

5' TTGTCGACCATGGCGTCTCAAGGCAC 3'

CCL021 (28 mer) (SEQ ID No. 11)

5' TTTCTAGACTTTAAYTGTCAWACTCYTC 3'

in order to isolate the gene encoding the nucleoprotein (NP) of the equine influenza virus (Newmarket 2/93 strain) (Figure No. 5, SEQ ID No. 12) in the form of a PCR fragment of about 1520 bp. This fragment was purified and then digested with the restriction enzymes SalI and XbaI in order to isolate a SalI-XbaI fragment of 1506 bp containing the Newmarket 2/93 EIV NP gene. This fragment was then ligated with the plasmid pVR1012 (see Example 7), previously digested with SalI and XbaI, in order to give the plasmid pPB245 (6389 bp).

**Example 13: Construction of the plasmid pPB246  
(Kentucky 1/94 EIV NP gene)**

An RT-PCR reaction according to the technique described in Example 6 was carried out with the genomic RNA of the equine influenza virus (EIV) (Kentucky 1/94 strain) (Daly et al. J. Gen. Virol. 1996, **77**, 661-671), prepared according to the technique described in Example 4, and with the following oligonucleotides:

CCL019 and CCL021 (Example 12) in order to isolate the gene encoding the nucleoprotein (NP) of the equine influenza virus (Kentucky 1/94 strain) (Figure No. 6, SEQ ID No. 13) in the form of a PCR fragment of about 1520 bp. This fragment was purified and then digested with the restriction enzymes SalI and XbaI in order to isolate a SalI-XbaI fragment of 1506 bp containing the Kentucky 1/94 EIV NP gene. This fragment was then ligated with the plasmid pVR1012 (see Example 7), previously digested with SalI and XbaI, in order to give the plasmid pPB246 (6389 bp).

**Example 14: Construction of the plasmid pPB156 (BHV-1 gB gene)**

Its construction is described in WO-A-98 03200.

**Example 15: Construction of the plasmid pAB087 (BHV-1 gD gene)**

Its construction is described in WO-A-98 03200.

**Example 16: Construction of the plasmid pAB090 (PRV gB gene)**

Its construction is described in WO-A-98 03658.

**Example 17: Construction of the plasmid pPB098 (PRV gD gene)**

Its construction is described in WO-A-98 03658.

**Example 18: Construction of the plasmid pAB044 (CDV HA gene)**

Its construction is described in WO-A-98 03199.

**Example 19: Construction of the plasmid pAB036 (CDV F gene)**

Its construction is described in WO-A-98 03199.

**Example 20: Construction of the plasmid pAB041 (G gene of the rabies virus)**

Its construction is described in WO-A-98 03199.

**Example 21: Application in horses**

The vaccine tested is a mixture of 3 plasmids pCCL027 (Example 8), pAB142 (Example 10) and pPB245 (Example 12) containing and expressing, respectively, the HA, NA and NP genes of the EIV virus strain Newmarket 2/93. This mixture is combined or otherwise with the carbomer as according to the present invention.

The vaccination/challenge protocol was the following:

Group	Number of horses	Vaccine	Diluent	Dose
A	5	pCCL027 + pAB142 + pPB245	Saline solution	3 × 400 µg
B	5	pCCL027 + pAB142 + pPB245	Carbopol® 974P	3 × 400 µg
C	6	Commercial vaccine	---	1 commercial dose
D (controls)	5	---	---	---

Ponies (Welsh Mountain ponies) 7 to 8 months old, having no detectable antibodies against the H3N8 and H7N7 viruses, measured by the SRH (Single Radial Haemolysis) test, were used for this study. The ponies were randomly distributed into 4 groups.

The horses were vaccinated on D0 and D35 by the intramuscular route. The commercial vaccine used for group C was administered to the horses in a dose volume of 1 ml.

The ponies in groups A and B each received 2 doses of 5 ml on D0 and D35 by deep intramuscular injection into the neck.

On D56, three weeks after the second vaccination, each pony was infected by exposure to an aerosol obtained from about 1 ml of allantoic fluid containing a total of  $10^{7.3}$  EID<sub>50</sub> of influenza A-equi-



2/Sussex/89 virus, using an ULTRA 2000 model spraying device (De Vilbiss, Somerset PA), as described by Mumford et al., Equine Vet. J. 1990, 22, 93-98.

After the challenge, the ponies were monitored in order to observe the clinical signs (establishment of a clinical score) and the temperature. Nasal swabs were prepared daily from day 0 of the challenge up to the 10th day after the challenge in order to measure the quantity of virus excreted by each challenged horse.

Finally, blood samples were collected throughout the protocol, before and after the challenge (days D0, D7, D14, D35, D49, D56, D63 and D70) in order to measure the kinetics of appearance and the level of SRH and IHA antibodies (haemagglutinating antibodies) for each vaccinated group.

#### Example 22: Application in pigs

The efficacy of a plasmid vaccine, combined or otherwise with the carbomer, was studied in pigs in a vaccination/challenge model for Aujeszky's disease. The vaccine tested is a mixture of 2 plasmids pAB090 (Example 16) and pPB098 (Example 17) comprising and expressing, respectively, the gB and gD genes of the PRV virus. The mixture was combined or otherwise with the carbomer as according to the present invention. The vaccination/challenge protocol used was the following:

Group	Number of pigs	Vaccine	Diluent	Dose
A	6	pPB098 + pAB090	Saline solution	2 x 200 µg
B	6	pPB098 + pAB090	Carbopol® 974P	2 x 200 µg
C	6	Geskypur	---	1 commercial dose
D (controls)	6	---	---	---

On D0, the pigs in groups A and B were vaccinated with the mixture of the plasmids pPB098 and pAB090 (200 µg of each plasmid), combined or otherwise with the carbomer, by the intramuscular route, in a volume of 2 ml.

The pigs in group C received an injection of the commercial vaccine Geskypur (subunit vaccine, MERIAL, Lyon, France) by the intramuscular route in a volume of 2 ml.

The pigs in group D were not vaccinated.

On D21, all the pigs were challenged with 2 ml (at the rate of 1 ml per nostril) of a viral suspension of Aujeszky's challenge strain, strain NIA3 (1/5 dilution of a stock solution titrating  $10^{8.25}$  CCID<sub>50</sub>/ml).

After the challenge, the pigs were monitored for mortality and the delta G7 criterion (individual weighings on D0 and D7 of the challenge). Nasal swabs are prepared daily from D0 to D14 of the challenge in order to measure the quantity of virus excreted after the challenge.

Finally, blood samples were collected on D0, D7, D14, D21 and D28 of the protocol in order to measure the kinetics and the Aujeszky's disease virus (PRV) seroneutralizing antibody level. The anti-PRV ELISA antibodies of isotypes IgG1 and IgG2 were also measured in the sera collected in the vaccinated and nonvaccinated pigs.

### **Example 23: Application in bovines**

The efficacy of a plasmid vaccine, combined or otherwise with the carbomer, was studied in bovines in a vaccination/challenge model for infectious bovine rhinotracheitis (IBR) or BHV-1. The vaccine tested is a mixture of 2 plasmids pPB156 (Example 14) and pAB087 (Example 15) comprising and expressing, respectively, the gB and gD genes of the BHV-1 virus. The mixture was combined or otherwise with the carbomer as according to the present invention. The vaccination/challenge protocol used was the following:

Group	Number of calves	Vaccine	Diluent	Dose
A	6	pAB087 + pPB156	Saline solution	2 x 300 µg
B	6	pAB087 + pPB156	Carbopol® 974P	2 x 300 µg
C	6	Ibepur	---	1 commercial dose
D (controls)	6	---	---	---

On D0, the calves in groups A and B were vaccinated with the mixture of plasmid pAB087 and pPB156 (300 µg of each plasmid), combined or otherwise with the carbomer, by the intramuscular route, in a volume of 5 ml.

The calves in group C received an injection of the commercial vaccine Ibepur (subunit vaccine, Merial, Lyon, France) by the intramuscular route in a volume of 2 ml.

The calves in group D were not vaccinated.

On D21, groups A, B and C received a second injection of vaccine according to the same modalities as on D0.

On D35, the calves were challenged with 2.5 ml (at the rate of 1.25 ml per nostril) of a viral suspension of the BHV-1 challenge strain, strain B901 (1/5 dilution of a stock solution titrating  $10^{8.15}$  CCID<sub>50</sub>/ml).

After the challenge, the calves were monitored for clinical signs (establishment of a clinical score). Nasal swabs were prepared daily from D0 to D14 of the challenge in order to measure the quantity of virus excreted after the challenge. Finally, blood samples were collected on D0, D7, D14, D21, D35 and D49 of the protocol in order to measure the kinetics and the infectious bovine rhinotracheitis virus (BHV-1) seroneutralizing antibody level. The anti-BHV-1 ELISA

antibodies of isotypes IgG1 and IgG2 were also measured in these sera collected from vaccinated and non-vaccinated calves.

5                   **Example 24: Application in dogs**

The efficacy of a plasmid vaccine, combined or otherwise with the carbomer, was studied in dogs in a vaccination/challenge model for Carré's disease (CDV). The vaccine tested is a mixture of the 2 plasmids  
10 pAB044 (Example 18) and pAB036 (Example 19) comprising and expressing, respectively, the HA and F genes of the CDV virus. The vaccination/challenge protocol used was the following:

Group	Number of dogs	Vaccine	Diluent	Dose
A	6	pAB036 + pAB041	Saline solution	2 × 200 µg
B	6	pAB036 + pAB041	Carbopol® 974P	2 × 200 µg
C	6	EURICAN	---	1 commercial dose
D (controls)	6	---	---	---

15

The dogs in groups A, B and C were vaccinated on D0 and D28 by the intramuscular route. The dogs in groups A and B received, for each vaccination, an injection of plasmid solution containing 400 µg in  
20 total (2 × 200 µg) in a volume of 1 ml.

The dogs in group C were vaccinated with the vaccine EURICAN (CHPPI2) which is a vaccine marketed by Merial, Lyon, France. One commercial dose contains about 10<sup>4</sup> pfu of CDV Onderstepoort vaccinal strain as  
25 well as the valencies for vaccination against Rubarth's hepatitis, canine parvovirus and type 2 parainfluenza virus.

The challenge was performed on D49 by intracerebral administration of 1/10 dilution of the

CDV "Synder-Hill" challenge strain (batch prepared and provided by USDA, USA).

5 Clinical monitoring was performed daily for 21 days after the challenge in order to note the signs (general state, oculonasal symptoms, digestive symptoms, nervous symptoms, temperature) (notation according to the rules of the European Pharmacopoeia). The challenged dogs were also weighed once per week.

10 Protection was assessed on the following criteria:

- mean clinical scores for each group
- CDV viraemia level after challenge (measurement of the viral load in the lymphocytes on D56, D61, D66, D70)
- 15 - blood count on blood samples collected on D48, D54, D56, D59, D63 and D70 (that is to say days - 1, 5, 7, 10, 14 and 21 after challenge)
- weight variation after challenge.

20 For all these criteria, the mean levels for each group were also compared with each other and with the mean level for the control group.

Blood samples were collected on days D0, D14, D28, D56 and D70 for titration of the ELISA antibodies and Carré's disease virus seroneutralizing antibodies.

### Further Statement of the Invention

This invention provides for a DNA vaccine comprising a naked DNA incorporating and expressing *in vivo* a polynucleotide encoding an antigenic polypeptide, preferably a gene of a pathogenic agent, and at least one adjuvant compound chosen from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl derivative.

In one embodiment of the invention, the vaccine is characterized in that it comprises, as adjuvant compound, a polymer of acrylic or methacrylic acid cross-linked with a polyalkenyl ether of a sugar or polyalcohol.

In another embodiment of the invention, the vaccine is characterized in that the polymer is cross-linked with an allyl sucrose or with allylpentaerythritol.

In another embodiment of the invention, the vaccine is characterized in that it comprises, as adjuvant compound, a copolymer of maleic anhydride and ethylene cross-linked, for example, with divinyl ether.

In another embodiment of the invention, the vaccine is characterized in that the adjuvant compound is present in the vaccine in an amount of 0.01% to 2% w/v.

In another embodiment of the invention, the vaccine is characterized in that the concentration is 0.06 to 1% w/v, preferably 0.1 to 0.6% w/v.

In another embodiment of the invention, the vaccine is characterized in that the naked DNA is a plasmid.

In another embodiment of the invention, the adjuvant compound is a carbomer or an EMA<sup>®</sup>.

In yet another embodiment of the invention, the vaccine is characterized in that it comprises a naked DNA incorporating and expressing a sequence of a pig, horse, dog, bovine, cat or avian pathogen.

In a further embodiment of the invention, the vaccine is characterized in that it comprises at least one sequence of a pathogen chosen from:

- Aujeszky's disease virus
- porcine influenza virus
- porcine reproductive and respiratory syndrome virus
- porcine parvovirus

- hog cholera virus
- *Actinobacillus pleuropneumoniae*
- equine rhinopneumonia virus
- equine influenza virus
- Cl. Tetani
- Eastern encephalitis virus
- Western encephalitis virus
- Venezuelan encephalitis virus
- B. burgdorferi
- Canine Distemper virus
- canine parvovirus
- canine coronavirus
- canine herpesvirus
- rabies virus
- bovine herpesvirus types 1 or 5
- bovine respiratory syncytial virus
- bovine pestivirus
- bovine parainfluenza virus type 3
- feline leukaemia virus
- feline panleukopaemia virus
- feline infectious peritonitis virus
- feline herpesvirus
- feline calicivirus
- feline immunodeficiency virus
- Marek's disease virus
- Newcastle disease virus
- Gumboro disease virus
- avian infectious bronchitis virus
- avian infectious anaemia virus
- infectious laryngotracheitis virus
- avian leukosis virus

- avian pneumovirus
- avian influenza.

The present invention also provides for a method of enhancing the DNA vaccine incorporating and expressing *in vivo* a heterologous polynucleotide by adding an adjuvant chosen from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl derivative, as defined in the specification.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent to those skilled in the art that certain changes and modifications can be practiced.

Therefore, the description and examples should not be construed as limiting the scope of the invention, which is delineated by the appended claims.

44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218



What is claimed is:

1. A DNA vaccine comprising a naked DNA incorporating and expressing *in vivo* a polynucleotide encoding an antigenic polypeptide and at least one adjuvant compound chosen from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl derivative.
2. The vaccine according to Claim 1, characterized in that it comprises, as adjuvant compound, a polymer of acrylic or methacrylic acid cross-linked with a polyalkenyl ether of a sugar or polyalcohol.
3. The vaccine according to Claim 2, characterized in that the polymer is cross-linked with an allyl sucrose or with allylpentaerythritol.
4. The vaccine according to Claim 1, characterized in that it comprises, as adjuvant compound, a copolymer of maleic anhydride and cross-linked ethylene.
5. The vaccine according to Claim 1, characterized in that the adjuvant compound is present in the vaccine in an amount of 0.01% to 2% w/v.
6. The vaccine according to Claim 5, characterized in that the adjuvant compound has a concentration of 0.06 to 1% w/v.
7. The vaccine according to Claim 1, characterized in that the naked DNA is a plasmid.
8. The vaccine according to Claim 1, characterized in that it comprises a naked DNA incorporating and expressing a pig, horse, dog, bovine, cat or avian pathogen.
9. The vaccine according to Claim 8, characterized in that it comprises at least one pathogen chosen from:
  - Aujeszky's disease virus
  - porcine influenza virus
  - porcine reproductive and respiratory syndrome virus
  - porcine parvovirus
  - hog cholera virus
  - Actinobacillus pleuropneumoniae
  - equine rhinopneumonia virus
  - equine influenza virus

- Cl. Tetani
- Eastern encephalitis virus
- Western encephalitis virus
- Venezuelan encephalitis virus
- B. burgdorferi
- Canine Distemper virus
- canine parvovirus
- canine coronavirus
- canine herpesvirus
- rabies virus
- bovine herpesvirus types 1 or 5
- bovine respiratory syncytial virus
- bovine pestivirus
- bovine parainfluenza virus type 3
- feline leukaemia virus
- feline panleukopaemia virus
- feline infectious peritonitis virus
- feline herpesvirus
- feline calicivirus
- feline immunodeficiency virus
- Marek's disease virus
- Newcastle disease virus
- Gumboro disease virus
- avian infectious bronchitis virus
- avian infectious anaemia virus
- infectious laryngotracheitis virus
- avian leukosis virus
- avian pneumovirus
- avian influenza.

10. A method of enhancing a DNA vaccine which incorporates and expresses *in*

*in vivo* a heterologous polynucleotide by adding an adjuvant chosen from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl derivative, as defined in Claim 1.

11. The DNA vaccine of claim 1, wherein the polynucleotide is a gene of a pathogenic agent.
12. The vaccine of claim 4, wherein the ethylene is cross-linked with divinyl ether.
13. The vaccine of claim 6, wherein the adjuvant compound has a concentration of 0.06 to 1% w/v.
14. The vaccine of claim 1, wherein the adjuvant compound is a carbomer or an EMA<sup>®</sup>.

## **ABSTRACT OF THE DISCLOSURE**

yl0277

ATGAAGACAACCAATTATTTTGATACTACTGACCCATTGGGTCTACAGTCAAAAACCAACCAAGTGGCAAC  
AACACAGCCACATTEATGTCTGGGACACCATGCGTAGCAATGGAACATTGGTAAAAACAATACTGAT  
GACCAAATTGAGGTGACAAATGCTACTGAATTAGTCCAGAGCATTTCATAGGGAAAAATATGCAACAAC  
TCATATAGGGTTCTAGATGGAAGAAATTGCACATTAATAGATGCAATGCTAGGAGACCCCATTTGTGAT  
GATTTTCAGTATGAGAATTGGGACCTCTTCATAGAAAGAAGCAGCGCTTTCAGCAATTGCTACCCATAT  
GACATCCCTGACTATGCATCGCTCCGCTCCATTGTAGCATCCTCAGGAACATTAGAATTCACAGCAGAG  
GGCTTCACATGGACAGGTGTCACTCAAAACGGAAGAAGTGGAGCCTGCAAAAGGGGATCAGCCGATAGT  
TTCTTTAGCCGACTGAATTGGCTAACAAAATCTGGAAATTCTTACCCCATATTGAATGTGACAATGCCT  
AACAAATAAAAAATTTGGATAAACTATACATCTGGGGGATTCAATCACCCGAGCTCAAAACAAAGAGCAGACA  
AAATTATATATCCAAGAATCAGGACGAGTAACAGTCTCAACAGAAAGAAGTCAACAAACAGTATTCCTT  
AACATCGGATCTAGGCCCTGGGTCAAGGGTCAATCAGGCAGGATAAGCATATCTGGACCATTTGTAAAA  
CCTGGAGATATTCATATGATAAACAGTAATGGCACTTAGTTGCACCGCGGGGATATTTTAAATTGAGA  
ACAGGGAAAAAGCTCTGTATGAGATCAGATGCACTCATAGACACTTTGTGTGTCTGAATGTATTACACCA  
AATGGAAGCATCCCCAACGACAAACCATTTCAAAATGTGAACAAAATTACATATGGAAAAATGCCCCAAG  
TATATCAGGCAAAACACTTTTAAAGCTGGCCACTGGGATGAGGAATGTACAGAAAAGCAAATCAGAGGA  
ATCTTTGGAGCAATAGCCGGATTCATAGAAAACCGCTCGGAAGCAATCGTTGATCGGTGGTATGGATTTC  
CGATATCAAAAACCTGGGAAGCAACAGGACAAGCTGCAGATCTAAAGAGCACTCAAGCAGCCATAGACCAG  
ATCAATGGAAAAATTAAACAGAGTCAATTGAAAGGACCAATGAGAAATTCCATCAAAATAGAAAAGGAATTC  
TCAGAAGTAGAAGGGAGAATCCAGGATTTGGAGAAGTATGTAGAAGACACCAAAATAGACCTATGGTCC  
TACAATGCAGAATTGCTGGTGGCTCTAGAAAATCAACATACAATTGACTTTAACAGATGCAGAAATGAAT  
AAATTAATTCGAGAAGACTAGGCGCCAGTTAAGAGAAAACGGCGAAGACATGGGAGGTGGATGTTTTCAAG  
ATTACCACAAATGTGATAATGCATGCATTGGATCAATAAGAAATGGGACATATGACCAATTACATATAC  
AGAGATGAAGCATTTAAACAACCGATTTCAAATCAAAAGTGTGAGTTGAAATCAGGCTACAAAGATTGG  
ATACTGTGGATTTTCAATCGCCATATCATGCTTCTTAATTTGCGTTGTTCTATTGGGTTTCATTEATGTGG  
GCTTCCCAAAAAGGCAACATCAGGTGCAACATTTGCATTGA

SEQ ID NO:3

FIGURE 1

ATGAAGACAACCATTATTTTGATACTACTGACCCATTGGGTCTACAGTCAAAACCCAACCAGTGGCAA  
CAACACAGCCACATTATGTCTGGGACCCATCCAGTAGCAAATGGAACATTGGTAAAAACAATACTG  
ATGACCAAATTGAGGTGACAAATGCTACTGAATTAGTTTCAGAGCATTTC AATAGGGAAAATATGCAAC  
AACTCATATAGAGTTCTAGATGGAAGAAATTGCACATT AATAGATGCAATGCTAGGAGACCCCCACTG  
TGATGTCTTT CAGTATGAGAAATGGGACCTCTTCATAGAAAGAAGCAGCGCTTT CAGCAATTGCTACC  
CATATGACATCCCTGACTATGCATCGCTCCGGTCCATTGTTAGCATCCTCAGGAACATTGGAATT CACA  
GCAGAGGGATT CACATGGACAGGTGTCACTCAAAAACGGAAGAAGTGGAGCCTGCAAAAGGGGATCAGC  
CGATAGTTTCTTTAGCCGACTGAATTGGCTAAACAAAATCTGGAAACTCTTACCC CACATTGAATGTGA  
CAATGCCTAACAATAAAAAATTCGACAAACTATACATCTGGGGGATT C ATCACC CGAGCTCAAACCA  
CAGCAAAACAGAAATGTACATCCAAAGATCAGGACGAGTAA CAGTCTCAACAAAAAGAAGTCAACAAAC  
GATAATCCCTAATATCGGATCTAGACCGTGGGT CAGGGTCAATCAGGCAGGATAAGCATATACTGGA  
CCATTGTAAAACCTGGAGATATCCTAATGATAAAACAGTAA TGGCAACTT T AGTTGCACCGCGGGATAT  
TTTAAATTGAAAACAGGGAAAAAGCTCTGTBAATGAGATCAGATGCACCCATAGACATT TGTGTGTCTGA  
ATGTATTACACCAAATGGAAGCATCCCCAACGACAAAACCATTTTCAAATGTGAACAAAGTACATATG  
GAAAATGCCCCAAGTATATCAGGCAAAACACTTTTAAAGCTGGCCACTGGGATGAGGAATGTACCAGAA  
AAGCAAATCAGAGGAATCTTTGGAGCAATAGCGGGATT C ATAGAAAACGGCTGGGAAGGAATGGTTGA  
TGGGTGGTATGGATTCCGATATCAAAACTCGGAAGGAACAGGACAAGCTGCAGATCTAAAGAGCACTC  
AAGCAGCCATCGACCAGATTAATGGAAAATTAAACAGAGTGATTGAAAGGACCAATGAGAAATTCCAT  
CAAATAGAGAAGGAATTCTCAGAAGTAGAAGGGAGAA TCCAGGACTTGGAGAAGTATGTAGAAGACAC  
CAAAATAGACCTATGGTCTTACAATGCAGAATTGCTGGTGGCTCTAGAAAATCAACATACAATTGACT  
TAACAGATGCAGAAATGAATAAATTATTTCGAGAAGACTAGACGCCAGTTAAGAGAAAAACGCGGAAGAC  
ATGGGAGGTGGATGTTTCAAGATTTACCACAAATGTGATAATGCATGCATTGGATCAA TAAGAAATGG  
GACATATGACCATTACATATACAGAGATGAAGCATTAACAACCGATTTCAAATCAAAGGTGTTGAGT  
TGAAATCAGGCTACAAAGATTGGATACTGTGGATTTCATTGCCCATATCATGCTTCTTAATTTGCGTT  
GTTCTATTGGGTTTCATTATGTGGGCTTGCCAAAAAGGCAACATCAGATGCAACATTTCATTGGA

SEQ ID NO:5

FIGURE 2

ATGAACCCAAATCAAAAGATAATAACAATTGGATCTGCATCATTAGGAGTACTAATCCTCAAGGTCATT  
CTCCATGTAGTCAGCATTATAGTAACAGTACTGGTTCTCAATAACAATGGAACAGGTCTGAACTGCAAC  
GGGACGATCATAAGAGAGTACAATGAAACAGTAAGAGTAGAAAGAATCACCCAATGGTATAATACTAGT  
ACAATTGAGTACATAGAAAGATCTTCAAATGAATACTACATGAACAACACCGAACCACCTTTGTGAGGCC  
CAGGGCTTTGCACCATTTTCCAAAGACAATGGAATACGAATGGGTCGAGAGGCCATGTTTTTTGTAATA  
AGAGAACCTTTTGTATCATGTTGCCCCCTCAGAATGTAGAACCCTTTTTCCTCACACAGGGCTCACTTACTC  
AATGACAAACATTCTAACGGCACACTGAAGGACCGAAGTCCATATAGGACCTTTGATGAGTGTCAAAATA  
GGGCAATCACCTAATGTGTATCAAGCTAGGTTTGAATCGGTGGCATGGTCAGCAACAGCATGCCATGAT  
GGAAAAAATGCATGACAGTTGGAGTCACAGGGCCCGACAATCAAGCAGTTGCAGTAGTGAACATATGGA  
GGTGTTCGGTTGATATTATTAATTCATGGGCATGGGATATCTTAAGAACCCAAGAATCGTCATGCACC  
TGCATTAAAGGAGACTGTTATTTGGGTGATGACTGATGGACCGGCAAACAGGCAAGCTAAATATAGGATA  
TTCAAAGCAAAAAATGGAAGAATAATTTGGGCAGACTGATATAAGTTTCAATGGGGGACACATAGAGGAG  
TGTTCTTTGTTACCCCAATGAAGGGAAGGTGGAATGCATATGCAGGGACAACCTGGACTGGAACAAATAGA  
CCAATTCTGGTAATATCTTCTGATCTATCGTACACAGTCGGATATTTGTGTGCTGGCATTCCTCACTGAC  
ACTCCTAGGGGAGAGGATAGTCAATTCACAGGCTCATGTACAAGCCCTTTGGGAAATAAAGGATACGGT  
GTAAAAGGTTTTCGGCTTTTCGACAAGGAACTGACGTATGGGCCGGAAGGACAATTAGTAGGACTTCAAGA  
TCAGGATTTCGAAATAATAAAGATCAGGAATGGTTGGACACAGAATAGTAAAGATCAAATCAGAAGGCAA  
GTGATTATTGATAACCTAAATTTGGTCAGGATATAGCGGTTCTTTACATTGCCGGTTGAACTAACAAAA  
AAGGGATGTTTAGTCCCTGTTTTCTGGGTTGAAATGATTAGAGGTAAACCTGAAGAAACAACAATATGG  
ACCTCTAGCAGCTCCATTGTGATGTGTGGAGTAGATCATAAAGTTGCCAGTTGGTCATGGCAGATGGA  
GCTATTCTTCCCTTTTGACATCGATAAGATGTAA

SEQ ID NO:8

FIGURE 3

4 / 6

ATGAATCCAAATCAAAAGATAATAACAATTGGATCTGCATCATTTGGGAATATTAATCATCAACGTCATT  
CTCCATGTAGTCAGCATTATAGTAACAGTACTGGTCCTCAATAACAATGGAACAGGTCTGAACTGCAAA  
GGGACGATCATAAGAGAGTACAATGAAACAATAAGAGTAGAAAGAATTACTCAATGGTATAATACCACT  
ACAATTGAGTACATAGAGAGACCTTCAAATGAATACTACATGAACAACACCGAACCCTTTGTGAGGCC  
CAAGGCTTTGCACCATTTTCCAAAGATAATGGAATACGAATTGGGTCGAGAGGCCATGTTTTTGTAAATA  
AGAGAACCCTTTGTCTCATGTTCCGCCCTCAGAATGTAGAACCCTTTTTCCTCACACAGGGCTCATTTACTC  
AATGACAAACATTTCTAACGGCACAGTGAAGGACCGAAGTCCATATAGGACTTTGATGAGTGTCAAAATA  
GGGCAATCACCTAATGTGTATCAAGCTAGGTTTGAATCGGTGGCATGGTCAGCAACAGCATGGGATGAT  
GGAAAAAATGGATGACAGTTGGAGTCAACAGGGCCCGATAATCAAGCAATTGCAGTAGTGAACCTATGGA  
GGTGTTCGGGTGATATTTAATTCATGGGCAGGGGATATCTTAAGAACCCAAGAATCGTTCATGCACC  
TGCATTAAAGGAGACTGTTATTTGGGTGATGACTGATGGACCGGCCAAATAGGCAAGCTAAATATAGGATA  
TTCAAAGCAAAAGATGGAAGAATAATTGGGCAGACTGATATAAGTTTCAATGGGGACACATAGAGGAG  
TGTTCTTGTATACCCCAATGAAGGGGAAGGTGGAATGCATATGCAGGGACAACCTGGACTGGAACAAATAGA  
CCAATTCTGGTAATATCTTCTGATCTATCGTACACAGTCCGATATTTGTGTGCTGGCATTTCCCACTGAC  
ACTCCTAGGGGAGAGGATAGTCAATTCACAGGCTCATGTACAAGTCCCTTTGGGAAATAAAGGATACGGT  
GTAAAAGGTTTCGGGTTTCGACAAGGAAC TGACGTATGGGCCGGAAGGACAATTAGTAGGACTTCAAGA  
TCAGGATTCGAAATAATAAAAAATCAGGAATGGTTGGACACAGAACAGTAAAGACCAAATCAGAAGGCAA  
GTGATTATTGATAACCCAAATTTGGTCAGGATATAGCGGTTCTTTACATTTGCCGGTTGAACCTAACAAAA  
AAGGGATGTTTAGTCCCTGTTCCTGGGTTGAAATGATTAGAGGTAAACCTGAAGAAACAACAATATGG  
ACCTCTAGCAGCTCCATTTGTGATGTTGTGGAGTAGATCATAAAATTTCCAGTTGGTTCATGGCAGCATGGA  
GCTATTCTTCCCTTTGACATAGACAAGATGTAG

SEQ ID NO:9

FIGURE 4



ATGGCGTCTCAAGGCACCAACGATCTTATGAGCAGATGGAACTGATGGGGAACGCCAGAAATGC  
AACTGAAATCAGAGCATCTGTTCGGAAGGATGGTGGGAGGAATCGGCCGGTTTTTATGTTTCAGATGT  
GTACTGAGCTTAAATTAAACGACCATGAAGGGCGGCTGATTTCAGAACAGCATAACAATAGAAAGG  
ATGGTACTTTTCGGCATTCGACGAAAGAAGAAACAAGTACCTCGAGGAGCATCCAGTGTCTGGGAA  
AGACCCTAAGAAAACGGGAGGCCCGATATACAGAAGGAAAGATGGGAAATGGATAAGAGAACTCA  
TCCTCCATGATAAAGAGGAAATCATGAGGGTCTGGCGTCAGGCCAACAAATGGTGAAGATGCTACT  
GCTGGTCTTACCCATATGATGATCTGGCACTCCAATCTCAATGACACCACATACCAAAGAACAAG  
GGCTCTTGTTCGGACTGGGATGGATCCCAGAAATGTGCTCTCTGATGCAAGGATCAACCCCTCCAC  
GGAGATCTGGAGCTGCCGGTGTTCGAGTAAAAGGTGTTGGAACAATGATAATGGAATCATCAGG  
ATGATCAAACCGCGGGATAAATGATCGAAATTTCTGGAGAGGTGAAAATGGTCAAGAACCAGAAT  
TGCTTATGAAAGAAATGTGCAATATCCTCAAAGGGAAATTTCAAACAGCAGCACAACGGGCTAEGA  
TGGACCAAGTGAGGGAGGSCCGCAATCCTGGAAATGCTGAGATTGAGGATCTCATTCTTGGCA  
CGATCAGCACTCATTTTGAGAGGATCAGTAGCCATAAATCATGCCTACCTGCCTGTGTTTTATGG  
CCTTGACAGTAACCACTGGGTATGACTTTGAGAAGGAAGGATACTCTCTGGTTGGGATTGATCCTT  
TCAAACCTACTCCAGAACAGCCAAATTTTCAGTCTAATCAGACCGAAAGAAAATCCAGCACACAAG  
AGCCAGTTGGTGTGGATGGCATGCCATTCCTGCAGCATTTGAGGACCTGAGAGTTTTGAATTTTCAT  
TAGAGGAACAAAAGTAATCCCAAGAGGACAGTTGGCAACCAGAGGAGTGCAGATTGCTTCAAATG  
AAAACATGGAGACAATAGATTCTTAGCACACTCGAACTGAGAAGCAGATATTGGGCAATAAGGACC  
AGAAGTGGAGGAAACACCACTCAACAGAGAGCATCTGCAGGACAGATAAGTGTGCAACCTACTTT  
CTCAGTGCAGAGAAATCTTCCCTTTGAAAGAGCAACCATTAATGGCTGCATTTACTGGGAACACTG  
AGCGGAGGACTTCCGACATGAGAACGGAATCATTAAGGATGATGGAAAATGCCAAATCAGAAGAT  
GTGTCTTTCCAGGGGCGGGAGTCTTCGAGCTCTCGGACGAAAAGGCAACGAACCCGATCGTGCC  
TTCCTTTGACATGAGCAATGAAGGTCCTATTTCTTCGGAGACAATGCTGAGGAGTATGACAGTT  
AA

SEQ ID NO:12

FIGURE 5

ATGGCGTCTCAAGGCACCAAACGATCTTATGAGCAGATGGAACTGATGGGGAACGCCAGAAATGCAACT  
GAAATCAGAGCATCTGTGCGGAAGGATGGTGGGAGGAATCGGCCGGTTTTATGTTTCAGATGTGTACTGAG  
CTTAAACTAAACGACCATGAAGGGCGGCTGATTGAGAACAGCATAACAAATAGAAAGGATGGTACTCTCG  
GCATTGACGAAAGAAGAAACAAGTATCTCGAGGAGCATCCCAAGTGTCTGGGAAAGACCCCTAAGAAAACG  
GGAGGCCCCGATATACAGAAGGAAAGATGGGAAATGGATGAGAGAACTCATCCTCCATGATAAAGAAGAA  
ATCATGAGGATCTGGCGTCAGGCCAACAAATGGTGAAGACGCTACTGCTGGTCTTACTCATATGATGATC  
TGGCACTCCAATCTCAATGACACCACATACCAAAGAACAAGGGCTCTTGTTCGGACTGGGATGATCCC  
AGAATGTGCTCTCTGATGCAAGGCTCAACCCCTCCACGGAGATCTGGAGCCGCTGGTGTCTGCAGTAAAA  
GGTGTGGAACAATGGTAATGGAATCATCAGAATGATCAAACGCGGGATAAATGATCGGAATTTCTGG  
AGAGGTGAAAATGGTGAAGAACCAGAATTGCTTATGAAAGAATGTGCAATATCCTCAAAGGGAAATTT  
CAGACAGCAGCACAACGGGCTATGATGGACCAGGTGAGGGAAGGCCGCAATCCTGGAAACGCTGAGATT  
GAGGATCTCATTTTTCTTGGCAGCATCAGCACTTATTTTGAGAGGATCAGTAGCCCATAAATCATGCTTA  
CCTGCCTGTGTTTTATGGCCTTGCAGTAACCAGTGGGTATGACTTTTGAGAAGGAAGGATACTCTCTGGTT  
GGAATTGATCCTTTCAAACCTACTCCAGAACAGCCAAATTTTCAGTCTAATCAGACCGAAAGAAAACCCA  
GCACACAAGAGCCAGTTGGTGTGGATGGCATGCCATTTCTGCAGCATTTGAGGACCTGAGAGTTTTGAAT  
TTCATTAGAGGAACCAAAGTAATCCCAAGAGGACAGTTAGCAACCAGAGGAGTGCAAATTGCTTCAAAT  
GAAAACATGGAGACAATAGATTCTAGCACACTCGAACTGAGAAGCAAATATTGGGCAATAAGGACCAGA  
AGTGGAGGAAACACCAGTCAACAGAGAGCATCTGCAGGACAGATAAGTGTGCAACCTACTTTCTCAGTG  
CAGAGAAATCTTCCCTTTGAAAGAGCAACCATTTATGGCTGCATTCACTGGGAACACTGAAGGGAGGACT  
TCCGACATGAGAACGGAAATCATAAGGATGATGGAAAATGCCAAATCAGAAGATGTGTCTTCCAGGGG  
CGGGGAGTCTTCGAGCTCTCGGACGAAAAGGCAACGAACCCGATCGTGCCTTCTTTGACATGAGCAAT  
GAAGGGTCTTATTTCTTCGGAGACAATGCTGAGGAGTTTGACAATTAA

SEQ ID NO:13

FIGURE 6

Patent 3801109

**DECLARATION FOR PATENT APPLICATION (JOINT OR SOLE)**  
(Under 37 CFR § 1.63; with Power of Attorney)  
**FROMMER LAWRENCE & HAUG LLP. File No. 454313-**

As a below named inventor, I hereby declare that:  
My residence, post office address and citizenship are as stated below next to my name,  
I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention ENTITLED: "Adjuvant--containing DNA vaccines"

the specification of which

X is attached hereto.

X was filed on March 22, 1999 as International Application Serial No. PCT/FR99/00666  
with amendment(s) through \_\_\_\_\_ (if applicable, give dates).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Sec. 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:  
Prior Foreign Application(s) [list additional applications on separate page]: Priority Claimed:

Number:	Country:	Filed (Day/Month/Year):	Yes	No
98 04 409	FRANCE	3 April 1998	X	

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Sec. 1.56, which became available between the filing date of the prior application and the national or PCT international filing date of this application:  
Prior U.S. Application(s) [list additional applications on separate page]:  
Appl'n. Ser. No.: Filed (Day/Month/Year): Status:(patented, pending, abandoned):

I hereby appoint William S. Frommer, Registration No. 25,506, and FROMMER LAWRENCE & HAUG LLP, or their duly appointed associate, my attorneys, with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Courts in connection therewith, and specify that all communications about the application are to be directed to the following correspondence address:

William S. Frommer, Esq.  
c/o FROMMER LAWRENCE & HAUG LLP  
745 Fifth Avenue  
New York, New York 10151

Direct all telephone calls  
to: (212)588-0800 to the  
attention of:

William S. Frommer

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR(S): AUDONNET Jean-Christophe Francis

Signature: \_\_\_\_\_ Date: September 15, 2000

Full name of sole or first inventor:

Residence: 119, rue de Créqui - 69006 LYON France

Citizenship: French

Signature: MINKE Jules Maarten

Date:

Full name of 2nd joint inventor (if any): September 15, 2000

Residence: 23, avenue Molière 69960 CORBAS France

Citizenship: French

[Similarly list additional inventors on separate page]

Post Office Address(es) of inventor(s):

[if different from residence] Same

Note: In order to qualify for reduced fees available to Small Entities, each inventor and any other individual or entity having rights to the invention must also sign an appropriate separate "Verified Statement (Declaration) Claiming [or Supporting a Claim by Another for] Small Entity Status" form [e.g. for Independent Inventor, Small Business Concern, Nonprofit Organization, individual Non-Inventor].

PATENT  
454313-3160

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : AUDONNET Jean-Christophe Francis and MINKE Jules Maarten  
U.S. Serial No. : Not Yet Known  
Filing Date : Herewith  
For : ADJUVANT-CONTAINING DNA VACCINES  
Examiner : Not Yet Known  
Art Unit : Not Yet Known

745 Fifth Avenue  
New York, NY 10151

EXPRESS MAIL

Mailing Label Number: EL 375 195 811 US

Date of Deposit: October 2, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Kenneth Patterson  
(Typed or printed name of person mailing paper or fee)

Kenneth Patterson  
(Signature of person mailing paper or fee)

**STATEMENT TO SUPPORT FILING AND SUBMISSION OF  
SEQUENCE LISTINGS IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

Assistant Commissioner for Patents  
Washington, D.C. 20231


Dear Sir:

Enclosed are a paper copy and a computer readable copy of sequence listings. The undersigned hereby states that the content of the paper copy of the Sequence Listing for the above-referenced application filed, and the computer readable copy, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), are the same.

In the unlikely event that the Patent Office determines that an extension and/or other relief is required as a result of this statement, applicants petition for any required relief including extensions of time and authorize the Assistant Commission to charge the cost of such petitions and/or other fees due to our **Deposit Account No.: 50-0320**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP  
Attorneys for Applicants

By 

Thomas J. Kowalski  
Reg. No. 32,147  
Tel. (212) 588-0800  
Fax (212) 588-0500

TJK:cd  
Encs.CAD0850

SCANNED, # \_\_\_\_\_

# SEQUENCE LISTING

<110> AUDONNET et al.

<120> ADUVANT CONTAINING DNA VACCINES

<130> 454313-3160

<140>

<141>

<150> PCT/FR99/00666

<151> 1999-03-22

<150> 98 04409 FRANCE

<151> 1998-04-03

<160> 13

<170> PatentIn Ver. 2.1

<210> 1

<211> 40

<212> DNA

<400> 1

ttgtcgactc aatcatgaag acaaccatta ttttgatact 40

<210> 2

<211> 34

<212> DNA

<400> 2

ttggatcctt actcaaatgc aaatgttgca cctg 34

<210> 3

<211> 1698

<212> DNA

<400> 3

atgaagacaa ccattatddd gatactactg acccattggg tctacagtca aaacccaacc 60  
 agtggcaaca acacagccac attatgtctg ggacaccatg cagtagcaaa tggaacattg 120  
 gtaaaaacaa taactgatga ccaaattgag gtgacaaatg ctactgaatt agtccagagc 180  
 atttcaatag ggaaaatatg caacaactca tatagggttc tagatggaag aaattgcaca 240  
 ttaatagatg caatgctagg agacccccat tgtgatgatt ttcagtatga gaattgggac 300  
 ctcttcatag aaagaagcag cgctttcagc aattgctacc catatgacat ccctgactat 360

gcacgcctcc ggtccattgt agcatcctca ggaacattag aattcacagc agagggggttc 420  
 acatggacag gtgtcactca aaacggaaga agtggagcct gcaaaagggg atcagccgat 480  
 agttttcttta gccgactgaa ttggctaaca aaatctggaa attcttacct catattgaat 540  
 gtgacaatgc ctaacaataa aaatttcgat aaactataca tctgggggat tcatcaccgc 600  
 agctcaaaca aagagcagac aaaattatat atccaagaat caggacgagt aacagtctca 660  
 acagaaagaa gtcaacaaac agtaatccct aacatcggat ctaggccgtg ggtcaggggt 720  
 caatcaggca ggataagcat atactggacc attgtaaaac ctggagatat tctaatagata 780  
 aacagtaatg gcaacttagt tgcaccgcgg ggatatttta aattgagaac agggaaaagc 840  
 tctgtaatga gatcagatgc actcatagac acttgtgtgt ctgaatgtat tacaccaaat 900  
 ggaagcatcc ccaacgacaa accatttcaa aatgtgaaca aaattacata tggaaaatgc 960  
 cccaagtata tcaggcaaaa cactttaaaag ctggccactg ggatgaggaa tgtaccagaa 1020  
 aagcaaatca gaggaatctt tggagcaata gcgggattca tagaaaacgg ctgggaagga 1080  
 atggttgatg ggtggtatgg attccgatat caaaactcgg aaggaacagg acaagctgca 1140  
 gatctaaaga gcaactcaagc agccatagac cagatcaatg gaaaattaaa cagagtgtat 1200  
 gaaaggacca atgagaaatt ccatcaaata gaaaaggaat tctcagaagt agaagggaga 1260  
 atccaggatt tggagaagta tgtagaagac accaaaatag acctatggtc ctacaatgca 1320  
 gaattgctgg tggctctaga aaatcaacat acaattgact taacagatgc agaaatgaat 1380  
 aaattattcg agaagactag gcgccagtta agagaaaacg cggaagacat gggaggtgga 1440  
 tgtttcaaga tttaccacaa atgtgataat gcatgcattg gatcaataag aaatgggaca 1500  
 tatgaccatt acatatacag agatgaagca ttaaacaacc gatttcaaat caaaagtgtt 1560  
 gagttgaaat caggctacaa agattggata ctgtggattt cattcgccat atcatgtctt 1620  
 ttaatttgcg ttgttctatt gggtttcatt atgtgggctt gccaaaaagg caacatcagg 1680  
 tgcaacattt gcatttga 1698

<210> 4

<211> 34

<212> DNA

<400> 4

ttggatcctt actcaaatgc aaatgttgca tctg

34

<210> 5

<211> 1698

<212> DNA

<400> 5

atgaagacaa ccattatctt gatactactg acccattggg tctacagtca aaaccaacc 60  
 agtggcaaca acacagccac attatgtctg ggacaccatg cagtagcaaa tggaacattg 120  
 gtaaaaaaca taactgatga ccaaatgtag gtgacaaatg ctactgaatt agttcagagc 180  
 atttcaatag ggaaaatatg caacaactca tatagagttg tagatggaag aaattgcaca 240  
 ttaatagatg caatgctagg agacccccac tgtgatgtct ttcagtatga gaattgggac 300  
 ctcttcatag aaagaagcag cgctttcagc aattgctacc catatgacat ccctgactat 360  
 gcacgcctcc ggtccattgt agcatcctca ggaacattgg aattcacagc agagggattc 420  
 acatggacag gtgtcactca aaacggaaga agtggagcct gcaaaagggg atcagccgat 480  
 agttttcttta gccgactgaa ttggctaaca aaatctggaa actcttacct cacattgaat 540  
 gtgacaatgc ctaacaataa aaatttcgac aaactataca tctgggggat tcatcaccgc 600

```

agctcaaacc aacagcaaac agaattgtac atccaagaat caggacgagt aacagtctca 660
acaaaaagaa gtcaacaaac gataatccct aatatcggat ctagaccgtg ggtcaggggt 720
caatcaggca ggataagcat atactggacc attgtaaaac ctggagatat cctaatagata 780
aacagtaatg gcaacttagt tgcaccgcgg ggatatttta aattgaaaac agggaaaagc 840
tctgtaatga gatcagatgc acccatagac atttgtgtgt ctgaattatt acaccaaattg 900
gaagcatccc caacgacaaa ccatttcaaa atgtgaacaa agttacatat ggaaaatgcc 960
ccaagtatat caggcaaaac acttttaaagc tggccactgg gatgaggaat gtaccagaaa 1020
agcaaatcag aggaatcttt ggagcaatag cgggattcat agaaaacggc tgggaaggaa 1080
tggttgatgg gtggtatgga ttccgatatc aaaactcggg aggaacagga caagctgcag 1140
atctaaaaga gcaactcaagc agccatcgac cagattaatg gaaaattaaa cagagtgatt 1200
gaaaggacca atgagaaatt ccatcaaata gagaaggaat tctcagaagt agaagggaga 1260
atccaggact tggagaagta tgtagaagac accaaaatag acctatggtc ctacaatgca 1320
gaattgctgg tggctctaga aaatcaacat acaattgact taacagatgc agaaatgaat 1380
aaattattcg agaagactag acgccagtta agagaaaacg cggaagacat gggaggtgga 1440
tgtttcaaga tttaccacaa atgtgataat gcatgcattg gatcaataag aaatgggaca 1500
tatgaccatt acatatacag agatgaagca ttaaacaacc gatttcaaat caaagtggtt 1560
gagttgaaat caggctacaa agattggata ctgtggattt cattcgccat atcatgcttc 1620
ttaatttgcg ttgttctatt gggtttcatt atgtgggctt gccaaaaagg caacatcaga 1680
tgcaacattt gcatttga
1698

```

<210> 6

<211> 35

<212> DNA

<400> 6

tttgtcgaca tgaayccaaa tcaaaarata ataac 35

<210> 7

<211> 32

<212> DNA

<400> 7

tttggatccy tacatcttrt cgatgtcaaa gg 32

<210> 8

<211> 1412

<212> DNA

<400> 8

```

atgaacccaa atcaaaagat aataacaatt ggatctgcat cattaggagt actaatcctc 60
aacgtcattc tccatgtagt cagcattata gtaacagtac tggttctcaa taacaatgga 120
acaggtctga actgcaacgg gacgatcata agagagtaca atgaaacagt aagagtagaa 180
agaatcaccc aatgggtataa tactagtaca attgagtaca tagaaagatc ttcaaatagaa 240
tactacatga acaacaccga accactttgt gagggccagg gctttgcacc attttccaaa 300
gacaatggaa tacgaattgg gtcgagaggc catgtttttg taataagaga accttttgta 360

```



tcatgttcgc	cctcagaatg	tagaaccttt	ttcctcacac	agggctcatt	actcaatgac	420
aaacattcta	acggcacagt	gaaggaccga	agtccatata	ggactttgat	gagtgtcaaa	480
atagggcaat	cacctaattg	gtatcaagct	aggtttgaat	cggtggcatg	gtcagcaaca	540
gcatgccatg	atggaaaaaa	tggatgacag	ttggagtcac	agggcccgac	aatcaagcag	600
ttgcagtagt	gaactatgga	gggtgttcgg	ttgatattat	taattcatgg	gcatgggata	660
tottaagaac	ccaagaatcg	tcatgcacct	gcattaaagg	agactgttat	tgggtgatga	720
ctgatggacc	ggcaaacagg	caagctaaat	ataggatatt	caaagcaaaa	aatggaagaa	780
taattgggca	gactgatata	agtttcaatg	ggggacacat	agaggagtgt	tcttgttacc	840
ccaatgaagg	gaaggtggaa	tgcatatgca	gggacaactg	gactggaaca	aatagaccaa	900
ttctggtaat	atcttctgat	ctatcgtaca	cagtcggata	tttgtgtgct	ggcattccca	960
ctgacactcc	taggggagag	gatagtcaat	tcacaggctc	atgtacaagc	cctttgggaa	1020
ataaaggata	cggtgtaaaa	ggtttcgggt	ttcgacaagg	aactgacgta	tgggcccggaa	1080
ggacaattag	taggacttca	agatcaggat	tcgaaataat	aaagatcagg	aatgggttga	1140
cacagaatag	taaagatcaa	atcagaaggc	aagtgattat	tgataaccta	aattgggtcag	1200
gatatagcgg	ttctttcaca	ttgccggttg	aactaacaaa	aaagggatgt	ttagtcccct	1260
gtttctgggt	tgaatgatt	agaggtaaac	ctgaagaaac	aacaatatgg	acctctagca	1320
gtccattgt	gatgtgtgga	gtagatcata	aagttgccag	ttggtcatgg	cacgatggag	1380
ctattcttcc	ctttgacatc	gataagatgt	aa			1412

<210> 9

<211> 1414

<212> DNA

<400> 9

atgaatccaa	atcaaaagat	aataacaatt	ggatctgcat	cattgggaat	attaatcatt	60
aacgtcattc	tccatgtagt	cagcattata	gtaacagtac	tggtcctcaa	taacaatgga	120
acaggtctga	actgcaaagg	gacgatcata	agagagtaca	atgaaacaat	aagagtagaa	180
agaattactc	aatgggtataa	taccagtaca	attgagtaca	tagagagacc	ttcaaataag	240
tactacatga	acaacaccga	accactttgt	gaggcccaag	gctttgcacc	attttccaaa	300
gataatggaa	tacgaattgg	gtcgagaggc	catgtttttg	taataagaga	accttttgtc	360
tcatgttcgc	cctcagaatg	tagaaccttt	ttcctcacac	agggctcatt	actcaatgac	420
aaacattcta	acggcacagt	gaaggaccga	agtccatata	ggactttgat	gagtgtcaaa	480
atagggcaat	cacctaattg	gtatcaagct	aggtttgaat	cggtggcatg	gtcagcaaca	540
gcatgccatg	atggaaaaaa	atggatgaca	gttggagtca	cagggcccg	taatcaagca	600
attgcagtag	tgaactatgg	agggtgttcg	gttgatatta	tttaattcatg	ggcaggggat	660
atcttaagaa	ccaagaatc	gtcatgcacc	tgcattaaag	gagactgtta	ttgggtgatg	720
actgatggac	cggcaaatag	gcaagctaaa	tataggatat	tcaaagcaaa	agatggaaga	780
ataattgggc	agactgatat	aagtttcaat	gggggacaca	tagaggagtg	ttcttgttac	840
ccaatgaag	ggaaggtgga	atgcatatgc	agggacaact	ggactggaac	aaatagacca	900
attctggtaa	tatcttctga	tctatcgtac	acagtcggat	atttgtgtgc	tggcattccc	960
actgacactc	ctagggggaga	ggatagtcaa	ttcacaggct	catgtacaag	tcctttggga	1020
aataaaggat	acggtgtaaa	aggtttcggg	tttcgacaag	gaactgacgt	atgggccgga	1080
aggacaatta	gtaggacttc	aagatcagga	ttcgaaataa	taaaaatcag	gaatgggttg	1140
acacagaaca	gtaaagacca	aatcagaagg	caagtgatta	tgataaccc	aaattggtca	1200
ggatatagcg	gttctttcac	attgccgggt	gaactaacaa	aaaagggata	gtttagtccc	1260
ctgtttctgg	gttgaaatga	ttagaggtaa	acctgaagaa	acaacaatat	ggacctctag	1320
cagctccatt	gtgatgtgtg	gagtagatca	taaaattgcc	agttggtcat	ggcacgatgg	1380

agctattctt ccctttgaca tagacaagat gtag

1414

<210> 10

<211> 26

<212> DNA

<400> 10

ttgtcgacca tggcgtctca aggcac

26

<210> 11

<211> 28

<212> DNA

<400> 11

tttctagact ttaaytgtca wactcytc

28

<210> 12

<211> 1497

<212> DNA

<400> 12

atggcgtctc aaggcaccaa acgatcttat gagcagatgg aaactgatgg ggaacgccag 60  
aatgcaactg aaatcagagc atctgtcggg aggatggtgg gaggaatcgg ccggttttat 120  
gttcagatgt gtactgagct taaattaaac gaccatgaag ggcggtgat tcagaacagc 180  
ataacaatag aaaggatggt actttcggca ttcgacgaaa gaagaaacaa gtacctcgag 240  
gagcatccca gtgctgggaa agaccctaag aaaacgggag gcccgatata cagaaggaaa 300  
gatgggaaat ggataagaga actcatcctc catgataaag aggaaatcat gagggtctgg 360  
cgtcaggcca acaatggtga agatgctact gctgggtctta cccatgatgat gatctggcac 420  
tccaatctca atgacaccac ataccaaaaga acaagggtc ttgttcggac tgggatggat 480  
cccagaatgt gctctctgat gcaaggatca accctccac ggagatctgg agctgccggg 540  
gctgcagtaa aagggtgttg aacaatgata atggaactca tcaggatgat caaacgcggg 600  
ataaatgatc gaaatttctg gagaggtgaa aatgggtcgaa gaaccagaat tgcttatgaa 660  
agaatgtgca atacctcaa agggaaattt caaacagcag cacaacgggc tatgatggaa 720  
ccaagtgagg gagggccgca atcctggaaa tgctgagatt gaggatctca ttttcttggc 780  
acgatcagca ctcatctgag aggatcagta gcccataaat catgcctacc tgctgtgtt 840  
tatggccttg cagtaaccag tgggtatgac tttgagaagg aaggatactc tctgggtggg 900  
attgatcctt tcaaactact ccagaacagc caaatcttca gtctaactcag accgaaagaa 960  
aatccagcac acaagagcca gttggtgtgg atggcatgcc attctgcagc atttgaggac 1020  
ctgagagttt tgaatttcat tagaggaaca aaagtaatcc caagaggaca gttggcaacc 1080  
agaggagtgc agattgcttc aaatgaaaac atggagaaca atagattcta gcacactcga 1140  
actgagaagc agatattggg caataaggac cagaagtgga ggaaacacca gtcaacagag 1200  
agcatctgca ggacagataa gtgtgcaacc tactttctca gtgcagagaa atcttccctt 1260  
tgaaagagca accattatgg ctgcatttac tgggaacact gagcggagga cttccgacat 1320  
gagaacggaa atcataagga tgatggaaaa tgccaaatca gaagatgtgt ctttccaggg 1380  
gcggggagtc ttcgagctct cggacgaaaa ggcaacgaac ccgatcgtgc cttcctttga 1440

catgacaatg aaggggtctta tttcttcgga gacaatgctg aggagtatga cagttaa 1497

<210> 13

<211> 1493

<212> DNA

<400> 13

atggcgctctc aaggcaccaa acgatcttat gagcagatgg aaactgatgg ggaacgccag 60  
aatgcaactg aaatcagagc atctgtcggg aggatggtgg gaggaatcgg ccggttttat 120  
gttccagatg tgtactgagc ttaaactaaa cgaccatgaa gggcggctga ttcagaacag 180  
cataacaata gaaaggatgg tactctcggc attcgacgaa agaagaaaca agtatctcga 240  
ggagcatccc agtgctggga aagaccctaa gaaaacggga ggcccgatat acagaaggaa 300  
agatgggaaa tggatgagag aactcatcct ccatgataaa gaagaaatca tgaggatctg 360  
gcgctcaggcc aacaatggtg aagacgctac tgctggtctt actcatatga tgatctggca 420  
ctccaatctc aatgacacca aagaacaagg gctcttggtt ggactgggat ggatcccaga 480  
atgtgctctc tgatgcaagg ctcaaccctc ccacggagat ctggagccgc tgggtgctgca 540  
gtaaaagggtg ttggaacaat ggtaatggaa ctcatcagaa tgatcaaacg cgggataaat 600  
gatcggaatt tctggagagg tgaaaatagg tcgaagaacc agaattgctt atgaaagaat 660  
gtgcaatatc ctcaaaggga aatttcagac agcagcacia cgggctatga tggaccaggt 720  
gaggggaaggc cgcaatcctg gaaacgctga gattgaggat ctcatcttct tggcacgata 780  
agcacttatt ttgagaggat cagtagccca taaatcatgc ctacctgcct gtgtttatgg 840  
ccttgacagta accagtgggt atgactttga gaaggaagga tactctctgg ttggaattga 900  
tcctttcaaa ctactccaga acagccaaat tttcagtcta atcagaccga aagaaaaccc 960  
agcacacaag agccagttgg tgtggatggc atgccattct gcagcatttg aggacctgag 1020  
agttttgaat ttcattagag gaaccaaagt aatccaaga ggacagttag caaccagagg 1080  
agtgcaaatt gcttcaaag aaaacatgga gacaatagat tctagcacac tcgaactgag 1140  
aagcaaatat tgggcaataa ggaccagaag tggaggaaaa caccagtcaa cagagagcat 1200  
ctgcaggaca gataagtgtg caacctactt tctcagtgca gagaaatctt ccctttgaaa 1260  
gagcaaccat tatggctgca ttactgggga aactgaagg gaggacttcc gacatgagaa 1320  
cggaatcat aaggatgatg gaaaatgcca aatcagaaga tgtgtcttcc caggggctgg 1380  
gagtcttcga gctctcggac gaaaaggcaa cgaacccgat cgtgccttcc tttgacatga 1440  
gcaatgaagg gtcttatttc ttcggagaca atgctgagga gtttgacaat taa 1493